Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Haploidentical Bone Marrow Transplant for Severe Sickle Cell Disease
NCT02757885Phase 2Completed
- Sponsor
- Emory University
- Start
- Jul 2019
- Primary completion
- Dec 2021
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in sickle cell disease (SCD), sponsored by Emory University. Primary endpoints: Event-free Survival Rate at 1 year, Primary Graft Rejection Rate at 42 days and 2 more. Started Jul 2019; status: completed.
02
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT02757885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02757885.